Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6‐OHDA‐lesioned rats
Identifieur interne : 000284 ( Main/Exploration ); précédent : 000283; suivant : 000285Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6‐OHDA‐lesioned rats
Auteurs : Maria Papathanou [Suède] ; Sarah Rose [Royaume-Uni] ; Andrew Mccreary [Pays-Bas] ; Peter Jenner [Royaume-Uni]Source :
- European Journal of Neuroscience [ 0953-816X ] ; 2011-06.
English descriptors
- KwdEn :
Abstract
Dyskinesia induction in Parkinson’s disease (PD) appears less marked with long‐acting dopamine agonists than with short‐acting L‐Dopa, but the relationship to duration of drug action is unknown. It is also unclear whether the duration of drug action affects the expression of established dyskinesia. This study compared the ability of L‐Dopa and four dopamine agonists of different duration of action to induce abnormal involuntary movements (AIMs) in 6‐hydroxydopamine (6‐OHDA)‐lesioned rats, and their ability to express established AIMs following prior exposure to L‐Dopa. 6‐OHDA‐lesioned rats were treated with saline, L‐Dopa/benserazide, apomorphine, ropinirole, pramipexole or pergolide once daily for 15 days. Repeated administration of the short‐acting dopamine agonists, apomorphine (duration 80 min) and ropinirole (duration 90 min) induced marked axial, limb and orolingual AIMs at peak effect. L‐Dopa (duration 100 min) produced moderate AIMs at peak effect, while administration of the long‐acting dopamine agonists, pramipexole (duration 150 min) and pergolide (duration 240 min) resulted in mild AIMs. In rats primed to exhibit severe AIMs following repeated L‐Dopa administration, acute administration of apomorphine, ropinirole and L‐Dopa induced severe AIMs. By contrast, pramipexole and pergolide evoked only mild–moderate AIMs. Again, there was a negative correlation between duration of effect and the severity of AIMs expressed. These studies show that both the induction and expression of AIMs in 6‐OHDA‐lesioned rats are related to the duration of action of dopaminergic drugs. These findings suggest that continuous dopaminergic stimulation could be used both to avoid dyskinesia induction and to improve motor function in late‐stage PD when troublesome dyskinesia is evident.
Url:
DOI: 10.1111/j.1460-9568.2011.07704.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6‐OHDA‐lesioned rats</title><author><name sortKey="Papathanou, Maria" sort="Papathanou, Maria" uniqKey="Papathanou M" first="Maria" last="Papathanou">Maria Papathanou</name></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name></author><author><name sortKey="Mccreary, Andrew" sort="Mccreary, Andrew" uniqKey="Mccreary A" first="Andrew" last="Mccreary">Andrew Mccreary</name></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:21B15318C543E544E3F3BD8FA645985A299D6FAE</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1460-9568.2011.07704.x</idno><idno type="url">https://api.istex.fr/document/21B15318C543E544E3F3BD8FA645985A299D6FAE/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001C07</idno><idno type="wicri:Area/Main/Curation">001938</idno><idno type="wicri:Area/Main/Exploration">000284</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6‐OHDA‐lesioned rats</title><author><name sortKey="Papathanou, Maria" sort="Papathanou, Maria" uniqKey="Papathanou M" first="Maria" last="Papathanou">Maria Papathanou</name><affiliation wicri:level="1"><country xml:lang="fr">Suède</country><wicri:regionArea>Ludwig Institute for Cancer Research and Department of Cell and Molecular Biology, Karolinska Institutet, Box 240, Nobels väg 3, SE‐171 77 Stockholm</wicri:regionArea><wicri:noRegion>SE‐171 77 Stockholm</wicri:noRegion></affiliation></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Disease Research Group, School of Biomedical Sciences, Kings College, Southwark, London SE1 8UB</wicri:regionArea><wicri:noRegion>London SE1 8UB</wicri:noRegion></affiliation></author><author><name sortKey="Mccreary, Andrew" sort="Mccreary, Andrew" uniqKey="Mccreary A" first="Andrew" last="Mccreary">Andrew Mccreary</name><affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Abbott Healthcare B.V, C J Van Houtenlaan 36, Weesp</wicri:regionArea><wicri:noRegion>Weesp</wicri:noRegion></affiliation></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Disease Research Group, School of Biomedical Sciences, Kings College, Southwark, London SE1 8UB</wicri:regionArea><wicri:noRegion>London SE1 8UB</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neuroscience</title><idno type="ISSN">0953-816X</idno><idno type="eISSN">1460-9568</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-06">2011-06</date><biblScope unit="volume">33</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2247">2247</biblScope><biblScope unit="page" to="2254">2254</biblScope></imprint><idno type="ISSN">0953-816X</idno></series><idno type="istex">21B15318C543E544E3F3BD8FA645985A299D6FAE</idno><idno type="DOI">10.1111/j.1460-9568.2011.07704.x</idno><idno type="ArticleID">EJN7704</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0953-816X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>L‐Dopa</term><term>Parkinson’s disease</term><term>abnormal involuntary movements</term><term>continuous dopaminergic stimulation</term><term>dopamine agonists</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dyskinesia induction in Parkinson’s disease (PD) appears less marked with long‐acting dopamine agonists than with short‐acting L‐Dopa, but the relationship to duration of drug action is unknown. It is also unclear whether the duration of drug action affects the expression of established dyskinesia. This study compared the ability of L‐Dopa and four dopamine agonists of different duration of action to induce abnormal involuntary movements (AIMs) in 6‐hydroxydopamine (6‐OHDA)‐lesioned rats, and their ability to express established AIMs following prior exposure to L‐Dopa. 6‐OHDA‐lesioned rats were treated with saline, L‐Dopa/benserazide, apomorphine, ropinirole, pramipexole or pergolide once daily for 15 days. Repeated administration of the short‐acting dopamine agonists, apomorphine (duration 80 min) and ropinirole (duration 90 min) induced marked axial, limb and orolingual AIMs at peak effect. L‐Dopa (duration 100 min) produced moderate AIMs at peak effect, while administration of the long‐acting dopamine agonists, pramipexole (duration 150 min) and pergolide (duration 240 min) resulted in mild AIMs. In rats primed to exhibit severe AIMs following repeated L‐Dopa administration, acute administration of apomorphine, ropinirole and L‐Dopa induced severe AIMs. By contrast, pramipexole and pergolide evoked only mild–moderate AIMs. Again, there was a negative correlation between duration of effect and the severity of AIMs expressed. These studies show that both the induction and expression of AIMs in 6‐OHDA‐lesioned rats are related to the duration of action of dopaminergic drugs. These findings suggest that continuous dopaminergic stimulation could be used both to avoid dyskinesia induction and to improve motor function in late‐stage PD when troublesome dyskinesia is evident.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li><li>Royaume-Uni</li><li>Suède</li></country></list><tree><country name="Suède"><noRegion><name sortKey="Papathanou, Maria" sort="Papathanou, Maria" uniqKey="Papathanou M" first="Maria" last="Papathanou">Maria Papathanou</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name></noRegion><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></country><country name="Pays-Bas"><noRegion><name sortKey="Mccreary, Andrew" sort="Mccreary, Andrew" uniqKey="Mccreary A" first="Andrew" last="Mccreary">Andrew Mccreary</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000284 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000284 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:21B15318C543E544E3F3BD8FA645985A299D6FAE
|texte= Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6‐OHDA‐lesioned rats
}}
| This area was generated with Dilib version V0.6.23. |  |